drug_type
RELEVANT_DRUG
intervention_type
Cellular/gene immunotherapy (CAR T-cell therapy)
drug_description
Off-the-shelf, partially HLA-matched allogeneic anti-CD19 chimeric antigen receptor (CAR) T-cell therapy administered intravenously after lymphodepletion; donor-derived T cells engineered to express a CD19-specific CAR that binds CD19 on malignant B cells, triggering T-cell activation, cytokine release, and cytotoxic killing.
nci_thesaurus_concept_id
C207799
nci_thesaurus_preferred_term
Allogeneic Anti-CD19 CAR T-cells ATA3219
nci_thesaurus_definition
A preparation of allogeneic human Epstein-Barr virus (EBV)-sensitized T-lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19), with a modified CD3zeta signaling domain 1xx, with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD19 CAR T-cells ATA3219 recognize and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. The use of allogeneic EBV T-cells minimizes the risks for graft-versus-host disease (GvHD). The modified CD3zeta signaling domain 1xx retains signaling capacity in 1 of 3 immune-receptor-tyrosine-based-activation-motif (ITAM) regions, which may help prevent counterproductive T-cell differentiation and exhaustion, and may enhance the anti-tumor activity of the CAR T-cells.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic donor-derived T cells engineered with a CD19-specific chimeric antigen receptor (with 1XX CD3zeta signaling) bind CD19 on malignant B cells, inducing T-cell activation, cytokine release, proliferation, and cytotoxic lysis of CD19+ cells; the EBV-sensitized allogeneic platform is intended to reduce GVHD risk.
drug_name
ATA3219
nct_id_drug_ref
NCT06256484